Department of Physiology and Pharmacology, School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
Department of Pharmacy, Federal University of Pará, Belém, Brazil.
Clin Exp Pharmacol Physiol. 2021 May;48(5):717-725. doi: 10.1111/1440-1681.13467. Epub 2021 Jan 27.
Trans-4-methoxy-β-nitrostyrene (T4MN) induced more potent vasorelaxant effects in resistance arteries from hypertensive rats than its parent drug, β-nitrostyrene 1-nitro-2-phenylethene (NPe). To better understand the influence of insertion of the electron-releasing methoxy group in the aromatic ring of NPe, we investigated vasorelaxant effects of T4MN in isolated pulmonary artery and compared them with those of NPe in view of the potential interest of T4MN in pulmonary arterial hypertension. T4MN and NPe both caused concentration-dependent vasorelaxation in pulmonary artery rings pre-contracted with either phenylephrine (1 µmol/L) or KCl (60 mmol/L), an effect unaffected by endothelium removal. In endothelium-intact preparations pre-contracted with phenylephrine, the vasorelaxant effect of T4MN was more potent than that of NPe. However, unlike NPe, this effect was significantly reduced following pretreatment with 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) (10 µmol/L, a guanylate cyclase inhibitor) or tetraethylammonium (5 mmol/L, a potassium channel blocker). T4MN abolished the CaCl -induced contractions in pulmonary artery preparations stimulated with phenylephrine (PHE) under Ca -free conditions in the presence of verapamil, to preferentially activate receptor-operated calcium channels. From these findings, we propose that T4MN evokes endothelium-independent vasorelaxant effects in isolated rat pulmonary artery, partially by inhibiting Ca influx through L-type Ca channels, as well as by activating soluble guanylate cyclase and potassium channels. The present results suggest the therapeutic potential of T4MN in treating pulmonary arterial hypertension.
反式-4-甲氧基-β-亚硝基苯乙烯(T4MN)在阻力血管中的血管舒张作用强于其母体药物β-亚硝基苯乙烯 1-硝基-2-苯乙烯(NPe)。为了更好地了解在 NPe 的芳环中插入供电子甲氧基基团对血管舒张作用的影响,我们研究了 T4MN 在离体肺动脉中的血管舒张作用,并与 NPe 进行了比较,因为 T4MN 可能对肺动脉高压有潜在的兴趣。T4MN 和 NPe 均能引起预先用苯肾上腺素(1μmol/L)或氯化钾(60mmol/L)收缩的肺动脉环浓度依赖性血管舒张,这种作用不受内皮去除的影响。在预先用苯肾上腺素收缩的内皮完整的制剂中,T4MN 的血管舒张作用强于 NPe。然而,与 NPe 不同的是,这种作用在预先用 1H-[1,2,4]恶二唑并[4,3-a]喹喔啉-1-酮(ODQ)(鸟苷酸环化酶抑制剂,10μmol/L)或四乙铵(钾通道阻滞剂,5mmol/L)预处理后显著降低。T4MN 可在维拉帕米存在的情况下,在无钙条件下消除苯肾上腺素(PHE)刺激的肺动脉制剂中由 CaCl 2 引起的收缩,从而优先激活受体操纵的钙通道。从这些发现中,我们提出 T4MN 通过抑制 L 型钙通道的 Ca 2+内流,以及激活可溶性鸟苷酸环化酶和钾通道,在离体大鼠肺动脉中引起非内皮依赖性的血管舒张作用。本研究结果提示 T4MN 在治疗肺动脉高压方面具有潜在的治疗作用。